Table 3.
Allele and genotype frequencies of MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms in COVID-19 patients with neurologic syndrome and healthy controls and related association analyses
| SNP | Allele /Genotype | COVID-19 cases with neurologic syndrome (n = 72) N% |
Healthy controls (n = 500) N% |
OR (95% CI) | P |
|---|---|---|---|---|---|
| MMP9 rs3918242 | T vs. C | 32 (22.2) | 134 (13.4) | 1.84 (1.00-3.40) | 0.049 |
| C (Reference) | 112 (77.8) | 866 (86.6) | - | - | |
| TT vs. CC | 6 (8.3) | 14 (2.8) | 3.54 (0.85–14.6) | 0.081 | |
| CT vs. CC | 20 (27.7) | 106 (21.2) | 1.55 (0.69–3.47) | 0.278 | |
| TT vs. CT + CC | 6 (8.3) | 14 (2.8) | 3.15 (0.77–12.8) | 0.107 | |
| TT + CT vs. CC | 26 (36.11) | 120 (24) | 1.78 (0.85–3.74) | 0.122 | |
| CC (Reference) | 46 (63.8) | 380 (76) | - | - | |
| HWE | P = 0.17 | ||||
| MMP3 rs3025058 | G vs. C | 46 (31.9) | 168 (16.8) | 2.23 (1.34–4.02) | 0.002 |
| C (Reference) | 98 (68.1) | 832 (83.2) | - | - | |
| GG vs. CC | 8 (11.1) | 6 (1.2) | 13.25 (2.73–64.2) | 0.001 | |
| GC vs. CC | 30 (41.6) | 156 (31.2) | 1.91 (0.90–4.02) | 0.087 | |
| GG vs. GC + CC | 8 (11.1) | 6 (1.2) | 10.29 (2.20–48.1) | 0.003 | |
| GG + GC vs. CC | 38 (52.7) | 162 (32.47) | 2.33 (1.15–4.72) | 0.018 | |
| CC (Reference) | 34 (47.2) | 338 (67.6) | - | - | |
| HWE | P = 0.06 | ||||
| MMP2 rs243865 | T vs. C | 32 (22.3) | 204 (20.4) | 1.11 (0.61–2.02) | 0.721 |
| C (Reference) | 112 (77.7) | 796 (79.6) | - | - | |
| TT vs. CC | 4 (5.5) | 18 (3.6) | 1.58 (0.32–7.82) | 0.571 | |
| CT vs. CC | 24 (33.3) | 168 (33.6) | 1.01 (0.48–2.16) | 0.959 | |
| TT vs. CT + CC | 4 (5.5) | 8 (3.6) | 1.57 (0.32–7.59) | 0.571 | |
| TT + CT vs. CC | 28 (38.9) | 186 (37.2) | 1.07 (0.52–2.20) | 0.844 | |
| CC (Reference) | 44 (61.2) | 314 (62.8) | - | - | |
| HWE | P = 0.16 |
SNP, Single nucleotide polymorphism; MMP, Matrix metalloproteinase; COVID-19, Coronavirus disease 2019; OR, Odds ratio; 95% CI, 95% Confidence interval; HWE, Hardy-Weinberg equilibrium